Group 1 - The core announcement is about the approval of a new manufacturer, Chongqing Boteng Pharmaceutical Technology Co., Ltd., for the active pharmaceutical ingredient (API) of Contizolam, which is essential for the production of Contizolam tablets [1] - The API produced by Boteng is intended for the commercial production of Contizolam tablets, a new generation of oxazolidinone antibiotics developed by the company, used for treating complex skin and soft tissue infections [1] - The approval of the API registration indicates that Boteng's product meets national drug review technical standards, providing an additional supplier option for the commercial production of Contizolam tablets, thereby reducing reliance on a single supply path and enhancing market competitiveness [1] Group 2 - The new API supplier will help stabilize raw material supply and optimize production costs, which is crucial for expanding market share and responding to competition from similar products [1]